For instance, EGFR-TKIs can enhance progression-free survival compared to conventional chemotherapy in lung adenocarcinoma patients, while most patients eventually developed resistance to EGFR-TKIs [7]. The gene discussed is EGFR; the disease is lung adenocarcinoma.